What is the effective treatment for my hypothalamic obesity?

Hello,

Welcome to icliniq.com.

I understand how distressing it can be to experience significant weight gain despite consistent efforts with diet and exercise, especially after surgery for a craniopharyngioma. Hypothalamic obesity is a rare and challenging condition that occurs when the part of the brain responsible for regulating hunger, metabolism, and energy balance, namely the hypothalamus, is affected by surgery or radiation. In such cases, standard weight-loss strategies often become much less effective.

The possible causes include:

• Hypothalamic obesity occurring after craniopharyngioma surgery.

• Hypothyroidism or other hormonal deficiencies related to pituitary axis dysfunction.

• Cushing syndrome or steroid-induced weight gain.

• Medication-related weight gain, such as that associated with hormone replacement therapy.

I would recommend the following investigations:

• A complete pituitary hormone profile.

• Thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), and growth hormone (GH).

• Fasting blood glucose.

• Glycated hemoglobin (HbA1c).

• Lipid profile.

• Body mass index (BMI) assessment.

• Imaging studies such as magnetic resonance imaging (MRI) of the hypothalamus and pituitary region.

The following conditions need to be ruled out:

• Metabolic disorders.

• Endocrine-related conditions.

• Obesity due to hormonal imbalance.

• Hypothyroidism.

• Diabetes mellitus.

I would suggest the following measures:

• Injection of Tirzepatide 2.5 milligrams administered subcutaneously once weekly, with dose escalation by 2.5 milligrams every four weeks to a target dose of 10 to 15 milligrams, based on tolerance and response.

• Long-term continuation is planned with regular monitoring of weight and metabolic parameters.

• Other options include optimization of pituitary hormone replacement therapy, structured lifestyle support focusing on diet and physical activity, and consideration of bariatric surgery in severe and refractory cases.

Regular follow-up is strongly recommended, especially after initiation of glucagon-like peptide-1 (GLP-1) receptor agonist therapy. Once laboratory reports and relevant investigations are available, they will be reviewed together to adjust the dosage if required, monitor weight trends and metabolic health, and plan further steps to optimize treatment safely and effectively. Video consultations may be used for timely review and guidance.

Preventive measures include lifestyle measures that focus on maintaining functional activity levels, staying physically active, following a balanced diet, and adhering to long-term treatment and follow-up plans.

I hope you are satisfied with my answer. For further queries, you can consult me at iCliniq.

Thank you.